btn-iconSearch btn-iconContact Donate

Author: dailypress_dev

LRRK2 Physiology in Parkinson’s Disease
Is the Xenomitochondrial Mouse an Ideal PD Model
Parkinson’s Progression Markers Initiative (PPMI)
Alpha-Synuclein as a Major Regulator of Iron
Improving Therapeutic Targeting of Dopaminergic Afferents
The Role of Long Non-Coding RNA’s in Parkinson’s Disease
Effect of LRRK2 Mutations on PD Associated Inflammation
A Biomarker Test for LRRK2 Blocking Drugs
Verification of a Long-Noncoding RNA in Blood as a Biomarker
LRRK2 and Type-1 Interferon
Pharmcological Targeting of the NLRP3 inflammasome
Shake It Up and Parkinson’s Victoria Working Together
Understanding LRRK2 S90/S935 Phosphorylation in important for therapeutic LRRK2 inhibitor Development
Are there Peripheral Changes in GBA Protein/Activity in Idiopathic Parkinson’s Disease Patients
Development of a Novel Tracer for Imaging A-Synuclein in Vivo
Blocking Inflammasome-induced Neuroinflammation in Parkinson’s Disease with a Potent, Orally Available Small Molecule
Objective Measurement for population screening therapy optimisation and target validation
Inflammatory Phenotypes in Differentiated Human LRRK2 and GBA Mutation IPS Cell Lines
Parkinson’s Grant Funded at NEURA to address Falls
Pharmacological Targeting of Inflammasome Activation Mechanisms in Synuclein Models of Parkinson’s Disease
Brain Derived Exosome Biomarkers as a Liquid Biopsy for Parkinson’s Disease
Targeting gut bacteria to treat Parkinson’s symptoms
Using Digital Spatial Profile to Screen Targetable Molecules to Halt Alpha-Synucleinopathy
Does Dopamine Cell Death Result from a Novel Proteinopathy in Parkinson’s Disease Brain?
Validation of Period1 as a Therapeutic Target to Improve Sleep and Circadian Dysfunction in Parkinson’s Disease
Screening for Precision Parkin Activators
Measuring mitochondrial respiration and stress signaling in blood cells as biomarkers of Parkinson’s Disease
Improve targeted and individualised treatments for Parkinson’s through reading the matrix of astrocytes
Association of Repetitive DNA Elements in Parkinson’s Disease Risk and Progression
Assessing LRRK2, GCase and cytokines in cryopreserved monocytes
Single Molecule Detection of Oligomeric Synuclein in body fluids
Photoreceptor-directed light therapy in Parkinson’s disease
Identification of apoptosis-associated speck-like protein containing a CARD (ASC) as a disease-modifying therapeutic target in Parkinson’s disease
More Than Pretty Pictures: Ion Imaging of Lipid Content and Flux Kinetics in Models of Parkinson’s Disease
Brain-penetrating antisense oligonucleotide to down-regulate alpha-synuclein
Targeting the Body’s Circadian Clock to Improve Sleep Quality in Parkinson’s Disease
Validating a novel glycolipid receptor as a disease-modifying therapeutic target for Parkinson’s disease
Validating the functional role of the pathogenic microbiome metabolite Trimethylamine (TMA) at the gut-brain axis in Parkinson’s disease
Development of an Anti-inflammatory Drug for the Treatment of Parkinson’s Disease
Electrophysiological modulators to protect neurons in Parkinson’s Disease
Elucidating cell type-specific PINK1 and PRKN expression in vivo
Sitala
Confirming the trans effect in PD Gene Regulation
Development of an Anti-inflammatory Drug for the Treatment of Parkinson’s Disease
Australian Parkinson’s Genetic Study (APGS)
Validation of RRx-001 as a novel disease-modifying therapeutic for Parkinson’s disease
Investigating the role of repeat expansions and mitochondrial dysfunction in Parkinson’s disease.
Characterisation of the Kir4.2 channel as a critical new target for Parkinson’s disease
Nix Gene Therapy as a Treatment for Parkinson’s Disease
Enhancing brain clearance mechanisms to limit Parkinson’s disease progression